ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2025
Interpretation of Positive Roche Elecsys SARS-CoV-2 Antigen Test Results: Value for Clinical Decisions.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Elecsys SARS-CoV-2 antigen test (Elecsys; Roche Diagnostics, Rotkreuz, Switzerland) is a quantitative test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen. Although the positive predictive value of the test is high, false-positive (FP) results are unavoidable. Furthermore, FP results can lead to unnecessary isolation of patients or exposure of FP patients to truly positive patients. Therefore, to minimize potential harm to FP patients, this study aimed to identify clinical cases that are likely to produce FP results and in which additional testing should be recommended. These recommendations should be based on the Elecsys test results and relevant clinical information. Correspondingly, a retrospective study was conducted using nasopharyngeal swab samples from symptomatic and asymptomatic patients with SARS-CoV-2 infection and patients who had close contact with a confirmed SARS-CoV-2 infection case between September 2021 and October 2023. Of the total 5989 samples, 302 tested positive in the Elecsys test. Thereafter, the reverse transcription-polymerase chain reaction test was performed on patient samples (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.